The global bacterial eye infection therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2024-2031). The most prevalent bacterial infections of the eye include stye or sty (hordeolum), conjunctivitis keratitis, blepharitis, ocular herpes, uveitis, endophthalmitis, and cellulitis, among others. The rise in the geriatric patients’ population, coupled with the awareness about minor eye disorders are the pivotal factors affecting the growth of the global bacterial eye infection therapeutics market. The geriatric population is already considered to be more prone to suffer from eye diseases. Adding to this, there are high unmet medical needs related to eye care which are further anticipated to augment the global market growth.
Get Free Sample link @ https://www.omrglobal.com/request-sample/bacterial-eye-infection-therapeutics-market
Further, the incidences of bacterial eye infections are projected to rise globally in the near future. The major causes of the same include inadequate eye hygiene habits, an increasing number of post-operative eye infections, coupled with the emergence of new pathogens. For instance, as per the survey conducted by the National Ambulatory Medical Care Survey, alone in the year 2005, over 4.0 million Americans made visits to ambulatory physicians for bacterial conjunctivitis. Approximately 70% of patients with acute conjunctivitis consult primary and urgent care providers, accounting for 1.0% of overall primary care office visits. Further, adenoviruses account for 65-90% of cases of viral conjunctivitis. In addition, the global incidence of herpes simplex keratitis was calculated at approximately 1.5 million with 40,000 new cases of severe monocular visual impairment or blindness a year.
Some key players operating in the market include Akorn, Inc., Novartis AG, and Bayer AG. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on.
Full report of Bacterial Eye Infection Therapeutics Market available @ https://www.omrglobal.com/industry-reports/bacterial-eye-infection-therapeutics-market
Market Coverage
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Akorn, Inc., Novartis AG, and Bayer AG.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Bacterial Eye Infection Therapeutics Market – Segmentation
By Product
- Ointments
- Eye Drops
- Drugs
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/bacterial-eye-infection-therapeutics-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.